AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma - LARVOL DELTA

Efficacy and safety of vunakizumab in the treatment of non-common subtypes of psoriasis: A case report of three Patients (EADV 2026) - No abstract available

Case report • Clinical • Dermatology • Immunology • Psoriasis

Successful Treatment of Generalized Pustular Psoriasis with Vunakizumab: A Case Series (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

Successful Treatment of Refractory Pyoderma Gangrenosum with Vunakizumab: A Case Report (EADV 2026) - No abstract available

Case report • Clinical • Pyoderma Gangrenosum

Effectiveness and Safety of Vunakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: A Preliminary Analysis of a Real-World Prospective Study (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Real-world efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a prospective cohort study analysing BMI as a predictor of response (EADV 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Vunakizumab Achieve Complete Remission of Severe Plaque Psoriasis in a 25-Year-Old Male with HIV Infection: A Case Report (EADV 2026) - No abstract available

Case report • Clinical • Dermatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Plaque Psoriasis • Psoriasis

Real-world efficacy and safety of vunakizumab in scalp psoriasis: a prospective cohort study (EADV 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Dermatology • Immunology • Psoriasis

Successful Treatment of A 75-year-old Male with Severe Plaque Psoriasis Using Vunakizumab (antiIL-17)- A Case Report (EADV 2026) - No abstract available

Case report • Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Successful Treatment of a Patient with Severe Plaque Psoriasis Complicated by Pustular Psoriasis Using Vunakizumab (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis • Pustular Psoriasis

Rapid Response to Vunakizumab in an Elderly Patient with Generalized Pustular Psoriasis Masquerading as Acute Generalized Exanthematous Pustulosis: A Case Report (EADV 2026) - No abstract available

Case report • Clinical • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

Vunakizumab in the Treatment of Severe Erythrodermic Psoriasis with Multiple Organ Dysfunction: A Case Report (EADV 2026) - No abstract available

Case report • Clinical • Dermatology • Immunology • Psoriasis

Successful Treatment of Severe Generalized Pustular Psoriasis With Concomitant Infection Using Vunakizumab in an 87-Year-Old Patient: A Case Report (EADV 2026) - No abstract available

Case report • Clinical • Dermatology • Immunology • Infectious Disease • Psoriasis • Pustular Psoriasis

Successful treatment of moderate-to-severe hidradenitis suppurativa with Anti-IL-17A Agent Vunakizumab (EADV 2026) - No abstract available

Dermatology • Hidradenitis Suppurativa • Immunology

Short-Term Efficacy Observation and Medication Analysis of Vunakizumab in the Treatment of Moderate-to-Severe Plaque Psoriasis (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Follicular Psoriasis Successfully Treated with Vunakizumab: A Case Report (EADV 2026) - No abstract available

Case report • Clinical • Dermatology • Immunology • Psoriasis

The impact of immunogenicity on the efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a post hoc analysis of a phase 3 trial (EADV 2026) - No abstract available

Clinical • P3 data • Retrospective data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Efficacy and Safety of Vunakizumab in the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Report of two Cases. (EADV 2026) - No abstract available

Clinical • Dermatology • Hidradenitis Suppurativa • Immunology

Efficacy and Safety of Vunakizumab in the Treatment of Moderate-to-Severe Plaque Psoriasis in Patients with High Body Weight (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Vunakizumab-induced severe ulcerative colitis during treatment of psoriatic arthritis: a case report and literature review. (PubMed, Front Immunol) - "Vunakizumab was immediately discontinued; intravenous methylprednisolone 60 mg/day was administered to induce remission. The early treatment period (within the first 3 months) represents a high-risk window. Upon diagnosis, immediate drug withdrawal, corticosteroid-induced remission, and prioritized conversion to an IL-23 inhibitor (such as guselkumab) may be considered as a potential option to achieve dual control of intestinal, skin, and joint disease."

Journal • Review • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Liver Failure • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL23A

Vunakizumab Treatment for Pediatric Generalized Pustular Psoriasis: Two Case Reports. (PubMed, J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Pediatrics • Psoriasis • Pustular Psoriasis

Successful treatment of hidradenitis suppurativa with vunakizumab: a case report and literature review. (PubMed, Front Immunol) - "After 8 weeks of treatment with vunakizumab, which offered a pharmacoeconomic advantage during the transition period before its inclusion in China's national insurance system, the patient showed marked improvement, with complete resolution of nodules, abscesses, and tunnels and no recurrence or significant adverse events during 10 months of follow-up. This case highlights the potential of vunakizumab in the treatment of HS and supports the pathogenic role of IL-17 in the disease."

Journal • Review • Dermatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • Pain • IL17A

A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis (clinicaltrials.gov) - P3 | N=208 | Active, not recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2026 ➔ Jan 2027

Enrollment closed • Trial completion date • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis with a high drug interruption rate during the COVID-19 pandemic: a post hoc analysis from a single center of a phase III trial. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - P3 | "Despite the high drug interruption rate in Huashan Hospital during COVID-19 pandemic, vunakizumab shows acceptable efficacy and safety for treating patients with moderate-to-severe plaque psoriasis. However, the long-term efficacy of vunakizumab appears attenuated in this single-center cohort compared with the overall phase III trial population."

Journal • P3 data • Retrospective data • Dermatology • Immunology • Infectious Disease • Novel Coronavirus Disease • Psoriasis • Respiratory Diseases

A prospective, single-center, randomized study to evaluate the efficacy and safety of changing the dosing schedule for Vunakizumab Injection in the treatment of moderate to severe plaque psoriasis in adults (ChiCTR) - P4 | N=60 | Not yet recruiting | Sponsor: Huashan Hospital, Fudan University; Huashan Hospital, Fudan University

New P4 trial • Dermatology • Immunology • Psoriasis

Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial. (PubMed, J Dermatolog Treat) - P3 | "However, treatment responses at W52 were almost not different between patients continuously receiving vunakizumab and those switching from placebo to vunakizumab, regardless of disease duration and disease severity. Vunakizumab shows satisfactory efficacy in patients with moderate-to-severe plaque psoriasis, regardless of psoriasis duration and severity."

Clinical • Journal • P3 data • Retrospective data • Dermatology • Immunology • Psoriasis • IL17A